Glaucoma lecturer likens preserved drops to processed foods-neither is the healthiest ideal

Article

 

San Diego-“Trying to reduce BAK load is the right thing to do overall,” said Michael Chaglasian, OD, associate professor at Illinois College of Optometry and chief of staff at the Illinois Eye Institute. In his lecture yesterday morning, Preservative vs. Preservative Free Medication in Glaucoma, Dr. Chaglasian made a strong case that there are several deleterious effects of BAK, which should prompt practitioners to avoid them in many cases.

Dr. Chaglasian admitted he wasn’t always concerned about BAK. In fact, he said he didn’t used to pay much attention to ocular surface disease in his glaucoma patients. But, the Dry Eye Work Shop (DEWS) report in 2007 was a wake-up moment for him. The DEWS conclusion that the elimination of preservatives from OTC lubricants was a huge leap forward in ocular surface care made him think more seriously about the effects of preservatives in the glaucoma meds he prescribed. He wondered, “If preservatives play such a big role in ocular surface health, how might they be affecting my glaucoma patients, who use them long term?”

Since effects of preserved drops in glaucoma treatment tend to be subtle and build up over time, they are often overlooked. “But they can have a significant impact,” he said. BAK has several effects on the ocular surface, including:

  • Decreased epithelial cell integrity

  • Increased conjunctival inflammatory cells

  • Loss of goblet cells

  • Reduced tear function

  • Reduced TBUT

Beyond it’s relationship to ocular surface disease, BAK is associated with filtration bleb failure in trabeculectomy patients and inflammatory cell infiltration in the trabecular meshwork. Furthermore, new research also suggests that BAK affects the eyelid muscles, causing incomplete blink and lagophthalmus in animal models.

Dr. Chaglasian recommended that doctors consider the following factors when prescribing topical medications as these contribute to preservative toxicity:

  • Concentration

  • Frequency and duration of use

  • Tear production and clearance

  • Contact lens use

  • Number and type of concurrent meds

  • Type of preservative

Not every patient needs to be treated with BAK-free drops but, he said, clinicians need an evaluation and workup to avoid harming at-risk patients.ODT

Newsletter

Want more insights like this? Subscribe to Optometry Times and get clinical pearls and practice tips delivered straight to your inbox.

Recent Videos
Presenters from the Collaborative Care Symposium 2025 give their key takeaways from their presentations.
Erin Tomiyama, OD, PhD, FAAO, offers actionable advice for myopia management and perspective for practitioners ready to refine their approach.
Extended lotilaner 0.25% therapy shows meibomian gland benefits
Mitch Ibach, OD, FAAO, details a presentation he gave with Tanner Ferguson, MD, at the Collaborative Care Symposium 2025.
Carolyn Majcher, OD, FAAO, details a Collaborative Care Symposium 2025 presentation given with Prethy Rao, MD.
Mitch Ibach, OD, FAAO, details the importance of identifying the best candidates and practicing comanagement for refractive surgery.
Lori Wright, JD, sat down to talk about a presentation at Collaborative Care Symposium about the risk under federal statutes and how to minimize that risk as an optometrist or an ophthalmic practice.
Rachelle Lin, OD, MS, FAAO, on collaborating more effectively on neovascular retinal cases
Mark Bullimore, MCOptom, PhD, details the importance of preparing optometric students for myopic patient care in a Collaborative Care Symposium (CCS) 2025 presentation.
Peter Hersh, MD, stated that the key takeaway from a handful of presentations he gave at CCS 2025 is that successfully treating patients with keratoconus is identifying the disease early.
© 2025 MJH Life Sciences

All rights reserved.